Evidence map›Paper›PMID 35626034›Full record

ArticleCancers2022

Integrin α2 and β1 Cross-Communication with mTOR/AKT and the CDK-Cyclin Axis in Hepatocellular Carcinoma Cells.

Mazen A Juratli, He Zhou, Elsie Oppermann, Wolf O Bechstein, Andreas Pascher, Felix K-H Chun, Eva Juengel, Jochen Rutz, Roman A Blaheta

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mazen A JuratliDepartment of General and Visceral Surgery, Goethe-University, 60590 Frankfurt am Main, Germany.
He ZhouDepartment of General and Visceral Surgery, Goethe-University, 60590 Frankfurt am Main, Germany.ORCID 0000-0003-4202-6009
Elsie OppermannDepartment of General and Visceral Surgery, Goethe-University, 60590 Frankfurt am Main, Germany.
Wolf O BechsteinDepartment of General and Visceral Surgery, Goethe-University, 60590 Frankfurt am Main, Germany.
Andreas PascherDepartment of General, Visceral and Transplant Surgery, Muenster University Hospital, 48149 Muenster, Germany.
Felix K-H ChunDepartment of Urology, Goethe-University, 60590 Frankfurt am Main, Germany.
Eva JuengelDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0002-6321-8707
Jochen RutzDepartment of Urology, Goethe-University, 60590 Frankfurt am Main, Germany.
Roman A BlahetaDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0002-0129-7972
Goethe University Frankfurt · DEJohannes Gutenberg University Mainz · DEUniversity Hospital Münster · DE

Funding

B. Braun Stiftung N/ANachwuchsförderung/Frankfurter Forschungsförderung (FFF) N/ARudolf Geißendörfer-Stiftung N/A
6 · The paper itself

Abstract

Integrin receptors contribute to hepatocellular carcinoma (HCC) invasion, while AKT-mTOR signaling controls mitosis. The present study was designed to explore the links between integrins and the AKT-mTOR pathway and the CDK-Cyclin axis. HCC cell lines (HepG2, Huh7, Hep3B) were stimulated with soluble collagen or Matrigel to activate integrins, or with insulin-like growth factor 1 (IGF1) to activate AKT-mTOR. HCC growth, proliferation, adhesion, and chemotaxis were evaluated. AKT/mTOR-related proteins, proteins of the CDK-Cyclin axis, focal adhesion kinase (FAK), and integrin-linked kinase (ILK) were determined following IGF1-stimulation or integrin knockdown. Stimulation with collagen or Matrigel increased tumor cell growth and proliferation. This was associated with significant alteration of the integrins α2, αV, and β1. Blockade of these integrins led to cell cycle arrest in G2/M and diminished the number of tumor cell clones. Knocking down the integrins α2 or β1 suppressed ILK, reduced FAK-phosphorylation and diminished AKT/mTOR, as well as the proteins of the CDK-Cyclin axis. Activating the cells with IGF1 enhanced the expression of the integrins α2, αV, β1, activated FAK, and increased tumor cell adhesion and chemotaxis. Blocking the AKT pathway canceled the enhancing effect of IGF on the integrins α2 and β1. These findings reveal that HCC growth, proliferation, and invasion are controlled by a fine-tuned network between α2/β1-FAK signaling, the AKT-mTOR pathway, and the CDK-Cyclin axis. Concerted blockade of the integrin α2/β1 complex along with AKT-mTOR signaling could, therefore, provide an option to prevent progressive dissemination of HCC.

Indexed as

AKT-mTOR pathwaygrowthhepatocellular carcinomaintegrinsinvasion

Identifiers

PMID35626034
PMCPMC9139686
OpenAlexW4280590781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.